N/A N=96 Circle of Life. Improving Capacity of Swampy Cree Community Members to Recognize People at Risk for Suicide
Suicide
Primary: SIRI Questionnaire Score — 12.90; 14.17; 14.83; 14.30 number of items correct — p=0.61
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=3,070 Young Adult Smoker's Treatment Demand
Smoking Cessation
Primary: Program Enrollment — .05 proportion of click-throughs who enroll
N/A N=495 WalkAide Compared to Ankle-Foot Orthosis (AFO) in Stroke Patients
Stroke
Primary: Gait Velocity — .682; .635 m/sec
Phase 3 N=433 Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
Arthritis · Arthritis, Rheumatoid · Autoimmune Diseases
Primary: Percentage of Participants Achieving Erythrocyte Sedimentation Rate (ESR)-Based American College of Rheumatology [ACR] 20 Response at Week 14 — 34.9 percentage of…
N/A N=118 Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients
Diabetes · Hypertension · Dyslipidemia
Primary: Percentage of Participans With A1c<7%, LDL Cholesterol <100mg/dL, Systolic Blood Pressure <130mm Hg and Diastolic Blood Pressure <80 mm Hg — 40.4; 21.6; 65.5; 39.9…
Phase 1 N=14 Oxytocin Treatment of Alcohol Withdrawal
Alcohol Withdrawal
Primary: Total Lorazepam Dosage (in Milligrams) — 16.5; 3.4 milligrams of lorazepam
Phase 4 N=4 An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
Pompe Disease · Glycogen Storage Disease Type II
Primary: Change From Baseline in Number of Patients With Anti-Recombinant Human Acid Alfa-glucosidase (Anti-rhGAA) Immunoglobulin G (IgG) Antibody at End of Study — 2; 2…
N/A N=51 Study on ASTRA TECH Implant System, OsseoSpeed™ Implants in Patients Missing All Teeth in the Upper Jaw, Restored With Provisional Teeth Within 24 Hours
Jaw, Edentulous
Primary: Implant Survival Rate — 93.10 percentage of implants
Phase 4 N=115 SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
Renal Function and Chronic Allograft Vasculopathy
Primary: Measured Glomerular Filtration Rate (mGFR), 12 Months After Heart Transplantation — 79.8; 61.5 mGFR ml/min
N/A N=15 Evaluation of the Motus GI CleanUp System During Screening Colonoscopy
CRC
Primary: Mean of All Subjects Colon Segments BBPS>=2 — 3 Mean of BBPS score per segment
Phase 2 N=29 Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: Probability of Overall Survival at One Year — 0.66 probability of overall survival at 1 yr.
N/A N=153 Clinical Evaluation of Ajust™ in Stress Urinary Incontinence
Female Stress Urinary Incontinence
Primary: Percentage of Patients Free of Stress Urinary Incontinence — 92.8 percentage of participants
N/A N=11 A Nutritional Supplement Capsule Containing Curcumin, Green Tea Extract, Polygonum Cuspidatum Extract, and Soybean Extract in Healthy Participants
Healthy, no Evidence of Disease
Primary: The Magnitude of Change in Blood Lymphocyte NF-kB Level — -40.51 Optical Density unit
Phase 2 N=378 Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth
HIV Infections · Meningitis
Primary: Number of Immunogenic Responders, With Response Defined as a 4-fold or Greater Increase in Serum Bactericidal Antibody Titers From Study Entry to Week 28 After 2 Doses…
Phase 2 N=122 To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
Prostate Cancer
Primary: Cumulative CD54 Upregulation Ratio Between Each of the Cohorts. — 29.53; 30.94; 26.67 Ratio ofCD54 molecules on BDS65:FP cells — p=0.5019